Aerami Therapeutics is a leading brand dedicated to revolutionizing the treatment of cardiopulmonary diseases. They offer innovative products and services aimed at improving the lives of patients and preventing disease development or progression. Each of their current product candidates is based on targeted molecules with promising clinical or preclinical track records, ensuring focused and efficient development plans.

One of their key focuses is combining therapies with advanced administration platforms to develop differentiated medicines. By doing so, they aim to extend and improve patients' lives. Aerami Therapeutics boasts a highly experienced leadership team, bringing together formulation, device development, clinical, and commercial expertise.

Led by their Executive Chairwoman of the Board, Anne Whitaker, who has a remarkable 30 years of extensive experience in the healthcare industry. Their Chief Operating Officer, Interim Chief Executive Officer, Joshua Ziel, holds a PhD in biology and has spent years focusing on strategic planning for potential reverse remodeling agents in pulmonary hypertension. Dr.

Ziel has a strong track record in program development. With their dedication to innovative treatments and seasoned leadership, Aerami Therapeutics is at the forefront of transforming the lives of patients with cardiopulmonary diseases